Peptidomannan

Peptidomannan: A Comprehensive Reference

Overview and Taxonomic Context

The term peptidomannan refers to a class of fungal glycoconjugate macromolecules in which mannose-rich polysaccharide chains are covalently linked to peptide (protein) backbones via O-glycosidic bonds. The term is not the name of a single, uniform compound but rather a structural designation for a family of related glycopeptides produced by various fungi, including both Basidiomycetes (club fungi, which include many edible and medicinal mushrooms) and certain Ascomycetes such as Penicillium species. Within the dietary supplement literature, the most extensively documented peptidomannan is the fraction designated KS-2, isolated from the culture mycelia of the shiitake mushroom Lentinus edodes (Berk.) Sing. — also now classified taxonomically as Lentinula edodes (Berk.) Pegler. It is important to note that, as of the current literature, peptidomannan/KS-2 has not achieved the regulatory status of a pharmaceutical drug in Western markets and is not the subject of large-scale human clinical trials; the available evidence base is predominantly preclinical (animal and in vitro).

Identity: Chemical and Botanical Characterization

Source Organisms

KS-2, exhibiting antitumor- and interferon-inducing action, was isolated from hot water extracts of mycelia of Basidiomycetes. The primary and most studied source organism is Lentinus edodes (shiitake mushroom). KS-2 was prepared by ethanol precipitation of the hot water extract of culture mycelia of Lentinus edodes KSLE 007, and was further purified by ECTEOLA-cellulose and Sephadex G-100 column chromatography based on the interferon-inducing activity.

Beyond Lentinus edodes, peptidomannan-type glycoconjugates have been identified in other fungal systems. The compositions of exocellular saccharide-containing polymers from six mutants of Penicillium charlesii incapable of growing on galactose were investigated. The polymers from the mutants contain a much smaller percentage of galactose than that reported for the peptidophosphogalactomannan (PPGM) from the wild-type organism. A polymer containing only one galactosyl residue per 49 mannosyl residues was investigated in detail. This polymer is a glycopeptide (peptidomannan) with an amino acid composition similar to that of peptidophosphogalactomannan and a mass of about 23,000 daltons.

Peptidomannan-class compounds are also structurally related to the mannoproteins found on the outer cell walls of Candida and Saccharomyces species. Mannoproteins can be divided into two classes, higher molecular weight peptidomannans (260 kDa) and lower molecular weight mannoproteins (50–66 kDa), both of which consist of similar mannans and disparate proteins or peptides which have distinct adhesion specificities.

Chemical Composition and Structure

KS-2 is mainly composed of alpha-linked mannose and contains a small amount of peptide which consists of serine, threonine and alanine with residual amounts of the other amino acids. The estimated molecular weight of KS-2 is between 6.0 × 10⁴ and 9.5 × 10⁴ daltons.

The structural linkage of the sugar and peptide components has been elucidated in related peptidomannan compounds. Treatment of peptidomannan with 0.4 N NaOH releases mannan, mannopentaose, mannotetraose, mannotriose, mannobiose, and mannose residues, which are attached to the peptide by O-glycosidic linkage to seryl and threonyl groups. This O-glycosidic attachment between the mannan chains and the serine/threonine residues of the peptide backbone is thus a defining structural feature of the peptidomannan class.

The homogeneity of KS-2 was confirmed by multiple analytical methods. Its homogeneity was revealed by CsCl density gradient centrifugation, electrophoresis on cellulose acetate and Sephadex G-100 and ECTEOLA-cellulose column chromatography.

Broader Fungal Cell Wall Context

The cells of the majority of yeasts contain mannose-containing polysaccharides that are often covalently attached to protein. These polysaccharides are predominantly α-D-mannopyranans that display a variety of sequences of linkage types in branched structures. A few of the branched mannans carry some β-D-mannopyranose residues in the side chains.

Cell wall mannoproteins (CWMPs) are non-covalently bound to the cell wall as phosphopeptidomannan (PPM) or covalently attached to β(1→6) glucan through remnant glycosylphosphatidylinositol (GPI) anchors, which is in turn attached to β(1→3) glucan or chitin, that form the inner cell wall layer.

Common Forms and Preparations

KS-2 is prepared by ethanol precipitation of the hot water extract of culture mycelia of Lentinus edodes, and further purified by ECTEOLA-cellulose and Sephadex G-100 column chromatography. In a broader dietary supplement context, extracts of Lentinus edodes mycelia — abbreviated as LEM (Lentinus Edodes Mycelia extract) — contain multiple bioactive fractions including KS-2 peptidomannan alongside other compounds such as lentinan (a β-glucan), eritadenine, and polyphenols. Mushrooms have been valued as food and health supplements by humans for centuries. They are rich in dietary fiber, essential amino acids, minerals, and many bioactive compounds, especially those related to human immune system functions. Mushrooms contain diverse immunoregulatory compounds such as terpenes and terpenoids, lectins, fungal immunomodulatory proteins (FIPs) and polysaccharides. Peptidomannan-containing extracts are encountered commercially as hot water extracts, spray-dried powders, and encapsulated mycelial biomass preparations, though these forms contain a mixture of compounds and are not standardized specifically for peptidomannan content in most commercially available products.

Traditional and Historical Use

Cultures and Time Periods

Peptidomannan as an isolated or named compound has no traditional use per se — it was first identified and named through modern laboratory fractionation in the 1970s. However, its source organism, Lentinus edodes (shiitake mushroom), has a deep and well-documented history of use in East Asian traditions. These mushrooms are renowned in Far East countries (e.g., Japan, China, Korea) as a food and medicine for thousands of years. In the year 199 A.D., Kyusuyu, a native tribe of Japan, offered the Japanese Emperor Chuai a shiitake mushroom. Even older documents record its use in ancient China, where it was referred to as "ko-ko" or "hoang-mo." The cultivation of this mushroom has been practiced for a thousand years, with its cultivation originating in China during the Sung Dynasty (960–1127). Both history and legend credit Wu San Kwung as the originator of shiitake cultivation.

As a versatile medicine and as a food in Asian countries, L. edodes has been cultivated in China and Japan for about 2000 years. Shiitake mushroom cultivation techniques were probably introduced to Japanese farmers by the Chinese between 1500 and 1600 A.D.

Traditional Preparations and Purposes

Lentinula edodes, known in Japan and more widely as shiitake, and as 'fragrant mushroom' (xiang gu) in China, has an extensive history in East Asia where it has been used in food and traditional medicine as a qi tonic to bolster strength, digestion, circulation and immunity for millennia. In traditional East Asian medicine, shiitake is regarded as energetically sweet and neutral, making it a gentle, nourishing tonic for the body, and has been used in traditional East Asian medicine for thousands of years to strengthen weakness, in particular of the Spleen and Stomach — the digestive centre.

Astragalus root (Huang Qi) and shiitake mushrooms (Lentinus edodes) are both considered medicinal foods and are frequently used in traditional Chinese medicine due to their anticancer and immunomodulating properties. The traditional preparation consisted principally of consuming the whole dried or fresh fruiting body of the mushroom, or decocting it in boiling water — a process which, incidentally, parallels the hot water extraction methodology later used in the laboratory to isolate KS-2.

Modern scientific isolation of peptidomannan as a distinct entity began in the late 1970s in Japan. A new antitumor and antiviral substance, KS-2, was prepared by ethanol precipitation of the hot water extract of culture mycelia of Lentinus edodes KSLE 007, as described by Fujii, Maeda, Suzuki and Ishida, working at the Department of Medical and Pharmaceutical Development, Kirin Brewery Co., Ltd., published in 1978.

Key Constituents and Active Compounds

Primary Bioactive Fraction: KS-2

The core bioactive peptidomannan fraction from shiitake mycelia is KS-2. Its structural characteristics are:

• Carbohydrate backbone: KS-2 is mainly composed of alpha-linked mannose.
• Peptide component: Contains a small amount of peptide which consists of serine, threonine and alanine with residual amounts of the other amino acids.
• Molecular weight: The estimated molecular weight of KS-2 is between 6.0 × 10⁴ and 9.5 × 10⁴ daltons.
• Linkage type: Mannan chains attached to the peptide via O-glycosidic bonds at seryl and threonyl residues, as established in structurally analogous peptidomannan systems from Penicillium charlesii.

From the harvest of the mycelium, amino acids (serine, threonine, alanine and proline), the KS-2 peptide, and α-mannan are obtained, which are capable of inducing the production of interferon and effectively inhibiting the development of cancer.

Related Compounds in the Source Organism

Lentinus edodes mycelia contain a broader array of bioactive compounds alongside the peptidomannan KS-2. Lentinus edodes has been valued as edible and medical resources. Polysaccharides have been known to be the most potent antitumor and immunomodulating substance in Lentinus edodes. Of particular note is lentinan, a β-1,3-glucan structurally distinct from KS-2 (an α-mannan-peptide conjugate). Lentinan, a β-1,3-glucan polysaccharide isolated from L. edodes, has been used clinically in Japan since the early 1980s because of its immunomodulatory and antitumor effects. KS-2 and lentinan thus represent two distinct classes of bioactive macromolecules within the same mushroom, with different structural backbones (α-mannan-peptide versus β-glucan) and potentially overlapping but distinct mechanisms.

Mechanisms of Action

Interferon Induction

The most extensively documented mechanism of KS-2 peptidomannan is its capacity to induce endogenous interferon (IF) production. Oral (PO) administration of KS-2 to adult DDI mice resulted in a peak serum interferon (IF) titer of 800 units (U)/ml 20 hours after administration with detectable levels persisting until 30 hours. After intraperitoneal (IP) injection, a peak serum IF titer of 1,600 U/ml was detected and it followed the same time course as that of oral administration.

The IF induced by KS-2 shared certain physico-chemical properties with the standard preparation of immune IF and was not neutralized by an antiserum against type I IF. This suggests the interferon induced by KS-2 belongs to the immune (Type II, or gamma) interferon class, not the classical Type I interferons, though this distinction was established by serological neutralization rather than direct molecular characterization.

Immunopotentiation via Host Defense Pathways

The antiviral and antitumor activities of KS-2 are considered to be mediated through host immunopotentiation rather than direct cytotoxicity or virocidal action. No virocidal or virostatic activities of KS-2 to the influenza virus were found in vitro. The protective activities of KS-2 against influenza virus infection in mice are discussed in view of the immunopotentiation of the host animals.

This host-mediated rather than direct-acting mechanism is consistent with the broader class of fungal polysaccharides and glycoconjugates. Earlier findings suggest lentinan exerts its antitumor effects by activating immune responses in the host rather than directly attacking cancer cells. The antitumor activity of lentinan was thought to require an intact T-cell component and was mediated through a thymus-dependent immune mechanism. While this specific mechanistic finding pertains to lentinan rather than KS-2, it establishes a consistent mechanistic paradigm for bioactive macromolecules from the same source.

Pattern Recognition Receptor (PRR) Engagement

The immune-activating properties of fungal mannans as a class are attributable to their recognition by pattern recognition receptors (PRRs) on innate immune cells. All of the major cell wall carbohydrate components of fungal walls serve as pathogen associated molecular patterns (PAMPs), which are recognised by the innate immune system through pattern recognition receptors (PRRs) on the surface of immune effector cells. Mannans, which are exposed on the outer surface of the cell wall, are recognised by a wide range of PRRs depending on the immune cell type. These include toll-like receptor 4 (TLR4), TLR2, and others. The mannose receptor (MR) is also involved in the induction of signaling pathways that promote cytokine production in response to fungal pathogens and mannans. TNF release by macrophages in response to C. albicans requires the recognition mediated by MR and TLR4 for N-linked mannans and O-linked mannans, respectively. Although these mechanistic findings are established for fungal mannans in the context of immune defense and pathogen recognition, they provide a framework for understanding how alpha-mannan-containing compounds such as KS-2 may engage host immune receptors.

Oral Bioavailability and Tissue Distribution

A critical question for any orally administered macromolecule is whether it is absorbed intact. A pharmacokinetic study directly addressing this question for KS-2 found that partial intact absorption does occur. F-KS (fluorescently labelled KS-2), when given orally, was absorbed partially via portal vein and intestinal lymphatics into the general circulation with intact molecular size. Moreover, F-KS was recovered in urine with concomitant breakdown in molecular weight. Histological evaluation revealed that F-KS was accumulated in the mesenteric lymph nodes, Peyer's patches, spleen, liver, and kidneys. The accumulation in Peyer's patches and mesenteric lymph nodes is mechanistically significant, as these are primary sites of gut-associated immune activation and could explain systemic immune effects triggered by orally administered KS-2.

Scientific Evidence by Area of Use

Antitumor Activity

Evidence level: Preclinical only (animal models); no controlled human clinical trials specifically for KS-2 peptidomannan have been identified in the peer-reviewed literature.

KS-2 suppressed the growth of Ehrlich as well as Sarcoma-180 tumors in mice when given either orally or intraperitoneally. KS-2 was prepared by ethanol precipitation of the hot water extract of culture mycelia of Lentinus edodes KSLE 007. KS-2 is also capable of inducing interferon in mice when dosed orally or intraperitoneally.

The antitumor mechanism in animal studies is believed to be immune-mediated. KS-2 suppressed the growth of Sarcoma 180 tumors and induced an interferon in mice, when given either orally or intraperitoneally. These studies are restricted to transplanted tumor models in rodents (Sarcoma-180, Ehrlich ascites tumors), which are standard screening models but do not translate directly or reliably to human oncology outcomes. No peer-reviewed human clinical trial data on KS-2 peptidomannan as an antitumor agent has been identified in this review.

Antiviral Activity

Evidence level: Preclinical (animal) only.

In mice infected intranasally with influenza A2 (H2N2) virus, KS-2 was found to possess significant protective activities. Efficacy of the agent was evidenced by an increase in survivor number, a prolongation of mean survival time, an inhibition of the development of lung consolidation induced by the viral infection and a decrease in virus titer in lung tissues. Both oral (PO) and intraperitoneal (IP) administrations of KS-2 protected mice against infection and significant antiviral activities were achieved not only by prophylactic but also chemotherapeutic administration.

A review of antiviral bioactive compounds from mushrooms confirms these findings, noting that in a study using peptidomannan extracted from Lentinus edodes mycelia, mice infected with influenza A virus (H2N2) were administered orally and intraperitoneally with peptidomannan, which enhanced survival and elevated IFN levels in the blood. All available antiviral evidence for KS-2 peptidomannan is preclinical (rodent models); no human antiviral efficacy trials have been identified in the reviewed literature.

Immunomodulatory Activity

Evidence level: Preclinical (in vivo and in vitro); very limited human data for the broader shiitake mycelial extract context.

The interferon-inducing capacity of KS-2 has been robustly demonstrated in animal models, as noted above. The broader class of mushroom-derived immunomodulatory polysaccharides and glycoconjugates has attracted considerable scientific attention. Mushrooms contain diverse immunoregulatory compounds such as terpenes and terpenoids, lectins, fungal immunomodulatory proteins (FIPs) and polysaccharides. The distributions of these compounds differ among mushroom species and their potent immune modulation activities vary depending on their core structures and fraction composition chemical modifications.

No controlled human clinical trials specifically isolating and evaluating KS-2 peptidomannan as a standalone intervention have been identified in the peer-reviewed literature through this review. Studies on LEM (Lentinus edodes mycelial extract), which contains KS-2 as one component among many, exist but do not permit attribution of effects specifically to the peptidomannan fraction.

Body Systems and Health Areas of Association

Based on the available preclinical evidence, peptidomannan (KS-2) is primarily associated with the following body systems:

• Immune system: Induction of endogenous interferon; immunopotentiation through lymphoid tissue accumulation (mesenteric lymph nodes, Peyer's patches, spleen).
• Oncology / antitumor defense: Suppression of transplanted tumor growth in rodents via host immune activation.
• Antiviral defense: Enhanced host resistance to influenza A virus infection in animal models, mediated through interferon induction rather than direct virucidal action.

As a medicinal agent, L. edodes exhibits antifungal/antibacterial, antiviral, antioxidant, immunomodulatory and antitumor activities. It is important to emphasize that these properties pertain to the whole organism and its various extracts; the attribution of specific activities exclusively to the peptidomannan fraction requires caution, as L. edodes contains numerous bioactive compounds.

Dosage Forms and Reported Doses

The following dosage information is reported directly from the scientific literature; none of these doses have been validated in human clinical trials for KS-2 peptidomannan specifically:

• Mouse antiviral studies (Suzuki et al., 1979): Oral (PO) administration of KS-2 to adult DDI mice resulted in a peak serum interferon (IF) titer of 800 units (U)/ml 20 hours after administration. The study reported both oral and intraperitoneal routes; the specific dose amounts in mg/kg are not reproduced in the accessible abstract but are detailed in the original Journal of Antibiotics publication.
• Mouse antitumor pharmacokinetic study (Yamashita et al., 1983): A peptidomannan fraction designated as KS-2 was subjected for distribution study after oral administration. KS-2, exhibiting antitumor- and interferon-inducing action, was isolated from hot water extracts of mycelia of Basidiomycetes. Dose amounts in this pharmacokinetic study are reported in the original journal article (Immunopharmacology, vol. 5, 1983) but are not reproduced here as they are animal-model-specific and have no verified human translation.
• Route flexibility: Animal studies uniformly demonstrate biological activity via both oral and intraperitoneal routes, with intraperitoneal dosing producing roughly double the peak interferon titer compared to oral dosing.

No dosing guidelines, recommended daily intakes, or pharmacopoeia monographs specifically for peptidomannan/KS-2 as a dietary supplement have been identified from authoritative bodies (NIH ODS, NCCIH, EMA, EFSA, WHO, or national pharmacopeias) in this review.

Safety Considerations

Note: The following safety information is based strictly on what is present in the peer-reviewed and institutional literature reviewed. No boilerplate safety language is included.

Absence of Formal Human Toxicology Data for KS-2

No formal Phase I human safety or toxicology trials for isolated KS-2 peptidomannan have been identified in the peer-reviewed literature. Human safety data on the source organism and its broader extracts exist but cannot be directly attributed to the peptidomannan fraction specifically.

Adverse Effects of the Source Organism (Lentinus edodes)

Shiitake benefits as an edible and medicinal mushroom used in traditional medicine, particularly in Japan and China, have been documented. Potential adverse effects such as digestive problems and allergic reactions are noted. A phenomenon known as shiitake dermatitis (flagellate erythema) has been documented in the medical literature following consumption of raw or undercooked shiitake, though this reaction is attributed to lentinan rather than to KS-2 peptidomannan specifically.

Accumulation in Immune Organs

Histological evaluation revealed that F-KS (labelled KS-2) was accumulated in the mesenteric lymph nodes, Peyer's patches, spleen, liver, and kidneys. The long-term significance of this tissue accumulation — particularly in liver and kidneys — has not been evaluated in any identified chronic human exposure study. This pharmacokinetic finding warrants attention in the design of any future safety studies.

Immunostimulatory Potential

Given that the mechanism of action of KS-2 centers on immunopotentiation and interferon induction, theoretical considerations arise regarding use in individuals with autoimmune conditions, those receiving immunosuppressive therapy (e.g., transplant recipients), or in settings where excessive interferon production could be detrimental. However, no clinical data documenting such interactions for KS-2 specifically have been identified in the reviewed literature. These concerns are inferred from the compound's established mechanism and from general principles applicable to immunostimulatory agents.

Evidentiary Limitations and Summary

Peptidomannan, particularly in the form of the KS-2 fraction from Lentinus edodes mycelia, represents a well-chemically characterized glycopeptide with reproducible preclinical biological activities documented in peer-reviewed publications dating from 1978 to 1983. Its primary activities — antitumor effects in rodent transplanted tumor models, induction of endogenous type II interferon, and antiviral protection against influenza in mice — are internally consistent and mechanistically coherent, centering on host immunopotentiation rather than direct cytotoxicity.

However, the evidentiary base has several significant limitations:

• All identified efficacy data are from animal (murine) models; no controlled human clinical trials specifically evaluating isolated KS-2 peptidomannan have been identified.
• The compound has not been the subject of systematic reviews or meta-analyses.
• No authoritative regulatory or pharmacopoeia monograph specifically covering KS-2 peptidomannan as a dietary supplement has been identified from NIH ODS, NCCIH, EMA, EFSA, or WHO.
• Commercial products containing shiitake mycelium extracts (LEM) are not standardized for KS-2 peptidomannan content, making extrapolation from research to supplement products unreliable.
• The distinction between KS-2 peptidomannan and the separately studied compound lentinan (β-glucan from L. edodes) must be maintained; these are structurally and mechanistically distinct molecules, and clinical evidence for lentinan cannot be attributed to KS-2 peptidomannan.

References

• Fujii T, Maeda H, Suzuki F, Ishida N. Isolation and characterization of a new antitumor polysaccharide, KS-2, extracted from culture mycelia of Lentinus edodes. J Antibiot (Tokyo). 1978;31(11):1079–90. PubMed PMID: 569140
• Suzuki F, Suzuki C, Shimomura E, Maeda H, Fujii T, Ishida N. Antiviral and interferon-inducing activities of a new peptidomannan, KS-2, extracted from culture mycelia of Lentinus edodes. J Antibiot (Tokyo). 1979;32(12):1336–45. PubMed PMID: 575532
• Yamashita A, Ohtsuka H, Maeda H. Intestinal absorption and urinary excretion of antitumor peptidomannan KS-2 after oral administration in rats. Immunopharmacology. 1983;5(3):209–220.
• Gander JE et al. Exocellular glycopeptide (peptidomannan) from a Penicillium charlesii mutant. Journal of Bacteriology. 1975;121(2):675–681.
• Klotz SA. Molecular bases of adhesion of Candida albicans. Trends Microbiol. 1997;5(3):120–4. PubMed PMID: 9147268
• Hall RA, Gow NAR. Mannosylation in Candida albicans: role in cell wall function and immune recognition. Mol Microbiol. 2013;90(6):1147–61. PMC4112839
• Netea MG et al. Fungal glycans and the innate immune recognition. Eur J Immunol. 2008. PMC4196476
• Zhong C et al. Immunomodulatory Effects of Edible and Medicinal Mushrooms and Their Bioactive Immunoregulatory Products. J Fungi. 2020;6(4):269. PubMed PMID: 33171663
• Zhao X et al. A polysaccharide from Lentinus edodes inhibits human colon cancer cell proliferation and suppresses tumor growth in athymic nude mice. Oncotarget. 2016. PMC5352182
• Khan A et al. A concise review of mushrooms antiviral and immunomodulatory properties that may combat against COVID-19. Food Chemistry: Molecular Sciences. 2022. ScienceDirect
• Pires TCF et al. A Review on General Nutritional Compounds and Pharmacological Properties of the Lentinula edodes Mushroom. Food and Nutrition Sciences. 2014;5:1353–1369. SCIRP
• Minari JB et al. Combining the Anticancer and Immunomodulatory Effects of Astragalus and Shiitake as an Integrated Therapeutic Approach. Nutrients. 2021;13(8):2564. PMC8401741
• Xu H et al. Polysaccharides in Lentinus edodes: isolation, structure, immunomodulating activity and future prospective. Crit Rev Food Sci Nutr. 2014. PubMed PMID: 24236998
• Zhang M et al. Characterization and immunomodulating activities of polysaccharide from Lentinus edodes. International Immunopharmacology. 2004;4(13):1617–1624.
• Ramberg JE, Nelson ED, Sinnott RA. Immunomodulatory dietary polysaccharides: a systematic review of the literature. Nutr J. 2010;9:54. PMC2998446